Arvisol (cannabidiol CR) / Echo Pharma - LARVOL DELTA

EICAS: Evaluation Study of New Compounds with Potential Use in Schizophrenia (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Central Institute of Mental Health, Mannheim | N=86 ➔ 0 | Trial completion date: Dec 2022 ➔ Jan 2025 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Jun 2022 ➔ Jan 2025

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • CNS Disorders • Psychiatry • Schizophrenia

EICAS: Evaluation Study of New Compounds With Potential Use in Schizophrenia (clinicaltrials.gov) - P1; N=86; Not yet recruiting; Sponsor: Central Institute of Mental Health, Mannheim; Trial completion date: Dec 2020 ➔ Dec 2022; Trial primary completion date: Jun 2020 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date